University of Sydney: Sydney welcomes NSW funding for biomedical research complex

The University of Sydney today welcomed the announcement by the NSW Government of $143.3 million over four years towards the establishment of a first-of-its-kind Australian health and technology complex in Sydney.
The Sydney Biomedical Accelerator (SBA) will be a state-of-the-art biomedical research complex that will fast track real-world health outcomes by integrating fundamental, clinical and patient-centred research. Located within the Tech Central precinct it will be a partnership between the NSW Government, Sydney Local Health District and University of Sydney in collaboration with a leading medical research institute, the Centenary Institute.

“The government’s commitment today will fundamentally improve health outcomes for people in NSW and we are so pleased to be partnering with them and the Sydney Local Health District to bring this vision to life,” Professor Mark Scott, Vice-Chancellor and President of the University of Sydney said.

“The Sydney Biomedical Accelerator will bring world class biomedical science and technology facilities to our city and accelerate the solutions to our most complex health challenges.

“We are proud to be key partners and are committed to utilising our renowned research expertise and experience with commercialisation to ensure the Accelerator is a success.”

Executive Dean and Pro Vice-Chancellor of the University’s Faculty of Medicine and Health Professor Robyn Ward said the Sydney Biomedical Accelerator would support multidisciplinary collaboration between world-leading teams of clinicians, scientists, engineers, computer scientists, entrepreneurs and research and industry partners.

“Once built, it will be an internationally significant clinical, teaching and research precinct, aligning with the redevelopment of Royal Prince Alfred Hospital and the NSW Government’s Tech Central project,” Professor Ward said.

“We congratulate the NSW Government on its commitment to life sciences and to future health research and commercialisation which will have far-reaching benefits.”

The SBA will offer a unique global concentration of biomedical research talent and research facilities and will be positioned to dynamically collaborate with industry and start-ups as part of a hospital, university and technology innovation ecosystem.

Early works for the Sydney Biomedical Accelerator will commence this year and initial occupation is expected to occur from 2026.